Organogenesis Q3 net income plummets to $0.2M on $116.9M revenue; cuts FY2022 guidance

Organogenesis Holdings Inc.

2022-Q3 EPS reported $0.06 revenue$335,377,000

Net revenue $116.9M (+3% YoY), but net income $0.2M vs $12.6M in Q3 2021.
Adjusted EBITDA $11.6M, down 46% YoY; adjusted net income $5.1M, down 68%.
FY2022 revenue guidance lowered to $448-465M, citing challenging physician office environment and reimbursement uncertainty.
SG&A expenses surged 27% to $79.3M, pressuring margins.
Cash $108M, debt $72.6M; no share repurchase or dividend changes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Organogenesis Holdings Inc. reported third quarter ended September 30, 2022 results: revenue $116.9 million, net income $0.2 million, EPS $0.00 per share. Guidance lowered.

Period: third quarter ended September 30, 2022
Revenue: $116.9 million
Net income: $0.2 million
EPS: $0.00 per share
Guidance: lowered
Result: reported results

Exact text from the filing

& Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results Summary: • Net revenue of $116.9 million for the third quarter of 2022, an increase of 3% compared to net revenue of $113.8 million for the third quarter of 2021. Net revenue for the third quarter of 2022 consists of: o

View on SEC.gov

Browse all earnings releases →

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023902

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.